Fibronectin - a risk factor or protection after intracoronary stenting?
https://doi.org/10.24884/1682-6655-2013-12-4-12-19
Abstract
This article focuses on one of the most interesting, popular in the body and at the same time a little-studied glycoproteins - fibronectin. The conceptual information about the sources, mechanisms and regulation of its formation. Particular emphasis is placed on the role of fibronectin in haemostasis and repair, as well as its participation in the development of complications after percutaneous coronary intervention in patients with coronary heart disease. Modern data on the use of fibronectin as a component of the drug coating intracoronary stents.
About the Authors
G. A. Berezovskaya
I. P. Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
M. A. Karpenko
V. A. Almazov Federal Center of Heart, Blood and Endocrinology
Russian Federation
Russian Federation
N. N. Petrishchev
I. P. Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
References
1. Березовская Г. А., Ганюков В. И., Карпенко М. А. Рестеноз и тромбоз внутри стента: патогенетические механизмы развития и прогностические маркеры // Росс. кардиолог. журн. 2012. № 6 (98). С. 91-95.
2. Гуриев С. Б. Ультраструктурная и иммунофлюоресцентная характеристика состояния миокарда вне зоны экспериментального инфаркта // Мед. журн. Узбекистана. 1989. № 5. С. 84-87.
3. Дзяк Г. В., Коваль Е. А., Иванов А. П. и др. Тип деградации фибронектина как новый дополнительный фактор риска тромботических и геморрагических осложнений острого инфаркта миокарда с зубцом Q // Сердце и сосуды. 2007. № 1 (17). С. 39-51.
4. Ким Л. Б., Березовская Г. А., Лайвин А. Н. и др. Динамика содержания фибронектина у больных в процессе раннего постинфарктного ремоделирования миокарда левого желудочка // Бюл. СО РАМН. 2002. № 4. С. 63-66.
5. Кузник Б. И., Васильев Н. В., Цыбиков Н. Н. Иммуногенез, гемостаз и неспецифическая резистентность организма. М., 1989. 320 с.
6. Allen-Hoffmann B. L., Crankshaw C. L., Mosher D. E. Transforming growth factor beta increases cell surface binding and assembly of exogenous (plasma) fibronectin by normal human fibroblasts // Mol. Cell Biol. 1988. № 8. Р 4234-4242.
7. Baiza E., Borsi L., Allemanni G. et al. Transforming growth factor beta regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts // FEBS Lett. 1988. № 228. Р. 42-44.
8. Blatti S. P., Foster D. N., Ranganathan G. et al. Induction of fibronectin gene transcription and mRNA is a primary response to growth-factor stimulation of AKR-2B cells // Proc. Nati. Acad. Sci. U.S.A. 1988. № 85. Р. 1119-1123.
9. Cofano F, Comoglio P. M., Landolfo S., Tarone, G. Mouse immune interferon enhances fibronectin production of elicited macrophages // Immunoi. 1984. № 133. Р. 3102-3106.
10. Chauhan A. K., Kisucka J., Cozzi M. R. et al. Prothrombotic effects of fibronectin isoforms containing the EDA domain //Arterioscler. Thromb. Vasc. Biol. 2008. № 28 (2). Р. 296-301.
11. Chiang H. Y., Korshunov V. A., Serour A. et. al. Fibronectin is an important regulator of flow-induced vascular remodeling // Arterioscler. Thromb. Vasc Bio. 2009. № 29 (7). Р. 1074-1079.
12. Choate J. J., Mosher D. F. Fibronectin concentration in plasma of patients with breast cancer, colon cancer, and acute leukemia // Cancer. 1983. № 51. Р. 1142-1147.
13. Davi G, Patrono C. Platelet activation and atherothrombosis // N. Engl. J. Med. 2007. Vol. 13. № 357 (24). Р. 2482-2494.
14. Farb A., Lindsay J. Jr., Virmani R. Pathology of bailout coronary stenting in human beings // Am. Heart J. 1999. № 137 (4 Pt 1). Р. 621-631.
15. Hoosein N. M., Brattain D. E., McKnight M. K. et al. Characterization of the inhibitory effects of transforming growth factor-beta on human colon carcinoma cell line // Cancer Res. 1987. № 47. Р. 2950-2954.
16. Hynes R. O. Patel R., Miller R. H. Migration of neuroblasts along preexisting axonal tracts during prenatal cerbellar development // J. Neurosci. 1986. № 6. Р 867-876.
17. Ignotz R. A., Massague J. Transforming growth factor-beta stimulates the expression of fibroilectin and collagen and their incorporation into the extracellular matrix // J. Biol. Chern. 1986. № 261. Р. 4337-4345.
18. Ignotz R. A., Endo T., Massague J. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-J3 // J. Biol. Chern. 1987. № 262. Р. 6443-6446.
19. Kandzari D. E., Leon M. B., Popma J. J. et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial // J. Am. Coll. Cardiol. 2006. Vol. 19. № 48 (12). Р. 2440-2447.
20. Klockers M., Pattersson T., Vartio T. et al. Fibronectin in exudative pleural effusions // Clin. Pathol. 1982. № 35. Р. 723-727.
21. Labat-Robert J., Marques M. A., N'Doye S. et al. Plasma fibronectin in French centenarians // Arch. Gerontol. Geriatr. 2000. № 31. Р. 95-105.
22. Luscher T. F., Steffel J., Eberli F. R. et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications // Circulation. 2007. № 115 (8). Р.1051-1058.
23. Lupi A., Secco G. G., Rognoni A. et al. Plasma fibrinogen levels and restenosis after primary percutaneous coronary intervention // J. Thromb. Thrombolysis. 2012. № 33 (4). Р. 308-317.
24. Mauviel A., Daireaux M., Redini E. et al. Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts // FEBS Lett. 1988. № 236. Р.47-52.
25. Mosesson M. W., Amrani D. L. The structure and biological activities of plasma fibronectin // Blood. 1980. Vol. 56. P. l45-158.
26. Marx S. O., Jayaraman T., Go L. O. et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells // Circ Res. 1995. № 76 (3). Р.412-417.
27. Maurer L. M., Tomasini-Johansson B. R., Mosher D. F. Emerging roles of fibronectin in thrombosis // Thromb. Res. 2010. № 125 (4). Р. 287-291.
28. Moon D. G., Kaplan J. E., Mazurkewicz J. E. The inhibitory effect of plasma fibronectin on collagen-induced platelet aggregation // Blood. 1986. № 67. Р. 450-457.
29. Moon D. G., Matayoshi B. M., Weston L. K. et al. Fibronectin inhibition ofplatelet thrombus formation in an in vivo porcine model of vascular injury // Thromb. Res. 1994. Vol. 15. № 76 (4). Р. 343-351.
30. Morrison P. R., Edsall J. T., Miller S. G. Preparation and properties of serum and plasma proteins; the separation of purified fibrinogen from fraction I of human plasma // J. Am. Chem. Soc. 1948. № 70 (9). Р. 3103-3108.
31. Mosher D. F., Williams E. M. Fibronectin concentration is decreased in plasma of severely ill patients with disseminated intravascular coagulation // J. Lab. Clin. Med. 1978. № 91, Р. 729-735.
32. Muller G., Behrens I., Nussbaumer U. et al. Inhibitory action of transforming growth factor beta on endothelial cells // Proc. Natl. Acad. Sci. U.S.A. 1987. № 84. Р. 5600-5604.
33. Ni H., Yuen P. S., Papalia J. M. et al. Plasma fibronectin promotes thrombus growth and stability in injured arteriolesroc // Natl. Acad. Sci. USA. 2003. Vol. 100. Is. 5. P.2415-2419.
34. Orem C., Celik S., Orem A. et al. Increased plasma fibronectin levels in patients with acute myocardial infarction complicated with left ventricular thrombus // Thromb. Res. 2002. № 105 (1). Р. 37-41.
35. Orem C., Durmus I., Kilinc K. et al. Plasma fibronectin level and its association with coronary artery disease and carotid intima-media thickness // Coron. Artery Dis. 2003. № 14 (3). Р. 219-224.
36. Patrzyk M., Hoene A., Jarchow R. et al. Time course of fibronectin in the peri-implant tissue and neointima formation after functional implantation of polyester-based vascular prostheses with different porosity in pigs // Biomed Mater. 2010. № 5 (5). 055003.
37. Reheman A., Yang H., Zhu G. et al. Plasmafibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand facto // Blood. 2009. Vol. 19. № 113 (8). Р. 1809-1817.
38. Roy P., Torguson R., Okabe T. et al. Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsets // Catheter Cardiovasc. Interv. 2007. Vol. 70. № 2. Р. 167-172.
39. Schachner M., Schoonmaker G., Hynes R. O. Cellular and subcellular localization of LETS protein in the nervous system // Brain Res. 1978. № 158. Р. 149-158.
40. Seebacher T., Manske M., Kornblihtt A. R., Bade E. G. Cellular fibronectin is induced by epidermal growth factor but not by dexamethasone or cyclic AMP in rat liver epithelial cells // FEBS Lett. 1988. № 239. Р. 113-116.
41. Serebruany V. L., Solomon S. R., Shustov A. R. et al. Survival in Acute Myocardial Infarction Induced by Coronary Ligation: Prognostic Relevance of Certain Hemostatic Factors During the Occlusion Phase // Journal of Thrombosis and Thrombosis. 1998. Vol. 5. № 1. Р. 29-35.
42. Sherman L. A., Lee I. Fibronectin: Blood turnover in normal animals and during intravascular coagulation // Blood. 1982. № 60. Р. 558-563.
43. Siri A., Carnemolla B., Raffanti S. et al. Fibronectin concentrations in pleural effusions of patients with malignant and non-malignant diseases // Cancer Lett. 1984. № 22. Р. 1-9.
44. Song K. S., Kim H. K., Shim W. et. al. Plasma fibronectin levels in ischemic heart disease // Atherosclerosis. 2001. № 154. Р. 449-453.
45. Tamkun J. W., Hynes R. O. Plasma fibronectin is synthesized and secreted by hepatocytes // J. Bioi. Chern. 1983. № 258. Р. 4641-4647.
46. Trial J., Rossen R. D., Rubio J. et al. Inflammation and ischemia: macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes // Exp. Biol. Med. (Maywood). 2004. № 229 (6). Р. 538-545.
47. Urban P., Gershlick A. H., Guagliumi G. et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry // Circulation. 2006. Vol. 113. № 11. Р. 1434-1441.
48. van der Hoeven B. L., SchalijM. J., van der Wall E. E. Percutaneous coronary intervention with stent placement versus bypass operation in symptomatic multiple-vessel disease; lessons from an observational study // Ned. Tijdschr. Geneeskd. 2005. Vol. 17. № 149 (51). Р. 2837-2840.
49. Virmani R., Kolodgie F. D., Farb A. Drug-eluting stents: are they really safe? //Am. Heart Hosp. J. 2004. № 2 (2). Р. 85-88.
50. Wang H. G., Yin T. Y., Ge S. P. et al. Biofunctionalization of titanium surface with multilayer films modified by heparin-VEGF-fibronectin complex to improve endothelial cell proliferation and blood compatibility // J. Biomed Mater. Res. A. 2013. № 101 (2). Р. 413-420.
51. Zhai Z., Wu J., XuX. et. al. Fibrinogen controls human platelet fibronectin internalization and cell-surface retention // J. Thromb. Haemost. 2007. № 5 (8). Р. 1740-1716.
Review
For citations:
Berezovskaya G.A., Karpenko M.A., Petrishchev N.N. Fibronectin - a risk factor or protection after intracoronary stenting? Regional blood circulation and microcirculation. 2013;12(4):12-19. (In Russ.) https://doi.org/10.24884/1682-6655-2013-12-4-12-19
Views:
475
Email this article 
